Clinical Trials Directory

Trials / Completed

CompletedNCT03632681

Effect of Intranasal Insulin on Cognitive Processes and Appetite

Interactions Between Metabolic, Cognitive and Reward Processes in Appetite - Effects of Intranasal Administration of Insulin

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
64 (actual)
Sponsor
University of Birmingham · Academic / Other
Sex
Female
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This study investigates the effect of intranasal insulin on cognitive processes (behavioural and neural) in healthy lean and obese female adults. All subjects will receive a single-dose of intranasal insulin and/or placebo (on different days) before participating in several cognitive tasks.

Detailed description

It is well established that eating behaviour is affected by metabolic signals (e.g. insulin, ghrelin, serotonin) and is also modulated via food reward processes. However, in humans, eating behaviour is a complex process, which involves habits, long-term goals and social interaction. Thus, recently it has been proposed that higher cognitive processes such as inhibitory control, attention and memory also modulate eating. Insulin seems to be involved in both metabolic processes and cognitive processes. In the last decade it has been shown that intranasal administration of insulin decreases food intake, especially in women, and enhances thermogenesis and memory. In addition intranasal insulin administration has been shown to affect brain areas related to homeostatic control, reward and memory. In the proposed study the investigators will examine the effect of intranasal insulin administration on eating, and on metabolic, reward and cognitive processes and their potential interplay. The investigators will also study the effect of body weight on the actions of insulin on these processes.

Conditions

Interventions

TypeNameDescription
DRUGIntranasal InsulinIntranasal insulin
DRUGIntranasal PlaceboIntranasal placebo manufactured to mimic smell of insulin

Timeline

Start date
2018-04-23
Primary completion
2019-04-01
Completion
2019-04-01
First posted
2018-08-15
Last updated
2019-05-02

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT03632681. Inclusion in this directory is not an endorsement.